je.st
news
Immuron Announces Statistically Significant Results of Triple-Action...
2016-01-12 18:22:08| Agriculture - Topix.net
Australian microbiome biopharmaceutical company Immuron Limited today announced that IMM-529, a first-in-class oral therapeutic, successfully demonstrated prevention of Clostridium difficile infection recurrence in over 77.8% of infected mice. The mouse model developed by Associate Professor Dena Lyras and her team at Monash University was designed to evaluate the effectiveness of IMM-529 when used in conjunction with standard of care antibiotic treatment.
Tags: results
significant
announces
statistically
Category:Agriculture and Forestry